Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Phase

N/A

Condition

Cancer/tumors

Platelet Disorders

Lymphoproliferative Disorders

Treatment

Teclistamab

Clinical Study ID

NCT05463939

CR109154

64007957MMY4001

Ages > 18
All Genders

Study Summary

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patient diagnosed with Relapsed or Refractory Multiple Myeloma
Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial

Study Design